StoneX Group Inc. Sells 11,105 Shares of CVS Health Co. (NYSE:CVS)

StoneX Group Inc. cut its holdings in CVS Health Co. (NYSE:CVS) by 28.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,467 shares of the pharmacy operator’s stock after selling 11,105 shares during the period. StoneX Group Inc.’s holdings in CVS Health were worth $1,278,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Ridgewood Investments LLC grew its holdings in shares of CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 450 shares in the last quarter. Stonebridge Financial Group LLC bought a new position in CVS Health in the fourth quarter valued at approximately $28,000. Hopwood Financial Services Inc. bought a new stake in shares of CVS Health during the 4th quarter worth approximately $29,000. Legacy Investment Solutions LLC bought a new position in shares of CVS Health in the third quarter valued at $31,000. Finally, Financial Perspectives Inc raised its position in CVS Health by 137.5% during the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator’s stock worth $36,000 after acquiring an additional 466 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the topic of several recent analyst reports. Barclays boosted their price objective on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. UBS Group lowered their price target on CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 11th. Wells Fargo & Company lifted their target price on CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Leerink Partners upgraded CVS Health from a “market perform” rating to an “outperform” rating and increased their price target for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Finally, Evercore ISI upped their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.39.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Michael F. Mahoney acquired 30,000 shares of CVS Health stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP James David Clark sold 7,513 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS opened at $67.88 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $75.27. The company has a market cap of $85.59 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 0.98 and a beta of 0.54. The stock has a fifty day moving average price of $62.72 and a 200-day moving average price of $57.83.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.92%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s payout ratio is presently 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.